CANTOS: landmark study, modest benefits—more research needed
Letter to the Editor
- 4 Downloads
All authors have contributed equally to the manuscript.
Compliance with ethical standards
Conflict of interest
Authors are affiliated to Ipca Laboratories Limited and are involved in research studies on anti-diabetic drugs.
- 1.Ridker PM, Everett BM, Thuren T, MacFadyen J, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.Google Scholar
- 2.Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739–48.Google Scholar
© Research Society for Study of Diabetes in India 2018